Founder
Attralus
Attralus is developing pan-amyloid removal (PAR) therapeutics that specifically target and eliminate toxic amyloid deposits in patients with systemic amyloidosis, addressing a critical gap in treatment options. This approach aims to reverse disease progression and improve patient outcomes, as current therapies do not remove amyloid from vital organs.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$197.8MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Systemic amyloidosis, a condition characterized by the accumulation of amyloid deposits in vital organs, presents a significant challenge due to its diverse nature and the lack of therapies that directly remove amyloid. Current treatments primarily focus on slowing disease progression, leaving a critical gap in addressing the underlying cause and reversing organ damage. Diagnosis is also a hurdle, with a large percentage of patients remaining undiagnosed.
Solution
Attralus is developing pan-amyloid removal (PAR) therapeutics designed to target and eliminate toxic amyloid deposits in patients with systemic amyloidosis. Their approach involves novel biologics and an amyloidosis-specific imaging agent to identify and treat all types and stages of the disease. By directly binding to and removing amyloid from affected organs and tissues, Attralus aims to transform the treatment paradigm and potentially reverse disease progression, offering a disease-modifying solution beyond current treatments.
Target Audience
The primary target audience includes patients with systemic amyloidosis, as well as physicians specializing in hematology, oncology, cardiology, and neurology who treat these patients.
Features
- Pan-amyloid removal (PAR) therapeutics designed to eliminate toxic amyloid deposits.
- Novel biologics that directly bind to amyloid for removal.
- Amyloidosis-specific PET imaging agent (124I-evuzamitide / AT-01) for diagnosis and monitoring.
- Pipeline targeting all types and stages of systemic amyloidosis.
- Focus on disease-modifying amyloid removal, going beyond symptom management.